Objective To estimate the prevalence and characteristics of fetal thrombocytopenia at the time of percutaneous umbilical cord sampling (PUBS) in pregnancies complicated by alloimmunization and to conduct a systematic review on fetal thrombocytopenia in these pregnancies. Study design Retrospective cohort study of all patients undergoing PUBS at our institution from 2000-2017. Clinical data, including fetal platelet counts, were abstracted from the medical record and analyzed with routine statistical procedures. A systematic review and meta-analysis were also conducted according to standard procedures. Result At first procedure, prior to any transfusion, 13/36 fetuses (36%) had thrombocytopenia: 11/36 (31%) had moderate thrombocytopenia and 2/36 (6%) had severe thrombocytopenia (14 patients had no platelet count at first procedure). The systematic review identified six studies, and the prevalence of fetal thrombocytopenia at the time of PUBS for alloimmunization was 18% (95% confidence interval 11%, 26%). Conclusion Thrombocytopenia is common and underappreciated in fetuses undergoing PUBS for alloimmunization.
Introduction
Maternal erythrocyte alloimmunization remains a continuing challenge, both from missed opportunities for Rh (D) immunoglobulin prophylaxis as well as alloimmunization with other antibodies [1] . Surprisingly, despite the fact that the antigens involved are not expressed on platelets, fetal thrombocytopenia has been incidentally noted in cases of maternal red-cell alloimmunization requiring percutaneous umbilical cord blood sampling (PUBS) and intrauterine transfusion (IUT) [2] [3] [4] [5] . Fetal thrombocytopenia can be defined as platelet count <150 × 10 9 /L and classified as moderate (50-150 × 10 9 /L) or severe (<50 × 10 9 /L) [2, 5] . However, to date, the frequency, clinical associations, and consequences of this thrombocytopenia are relatively poorly understood. Therefore, our objectives were to estimate the prevalence of fetal thrombocytopenia at the time of PUBS in pregnancies complicated by red-cell alloimmunization and to investigate the associations between fetal thrombocytopenia and procedural factors and neonatal outcomes. To complement our study we also performed a systematic review and meta-analysis of the prevalence of fetal thrombocytopenia in cases of red-cell alloimmunization.
Methods

Cohort study
This is a retrospective cohort study of all patients undergoing PUBS for alloimmunization at Barnes-Jewish Hospital in St. Louis from 2000 to 2017. Patients undergoing PUBS for other indications, such as non-immune hydrops, were excluded. The decision to proceed with PUBS was based either on serial amniocentesis with delta OD 450 or, more recently, on elevated middle cerebral artery Doppler velocity [6] . Demographic and clinical data were abstracted from the medical record. Patients were categorized by antibody status as anti-D alone, anti-D and other antibodies, or other antibodies only, based on their initial presentation. Fetal antigen status was not uniformly available. At our institution PUBS is performed using standard techniques. The umbilical vein at the cord insertion into the placenta is the usual target. One milliliter of fetal blood is taken in a heparinized syringe to the central laboratory for complete blood count, and an additional 1 mL sample is taken for immediate analysis of hemoglobin with a point-of-care device. In cases of fetal anemia, packed red blood cell transfusion is given to achieve a target hematocrit of 45%. Specifically, donor red blood cells are packed by the blood bank to achieve a donor hematocrit of~85-90%. Blood used for transfusion is type O, Rh negative, negative for any antibody to which the patient is alloimmunized, leukocyte reduced, irradiated, washed, negative for cytomegalovirus, negative for hemoglobin S, and, in recent years, tested to ensure it is negative for the Zika virus. If the fetus is hydropic, then the transfusion is given as a split transfusion over 2 days. Fetal paralysis is used rarely.
Demographic, clinical, and outcome data were obtained from the medical record. Descriptive statistics were used to characterize the cohort. Fetal thrombocytopenia was defined as platelet count <150 × 10 9 /L and was classified as moderate (50-150 × 10 9 /L) or severe (<50 × 10 9 /L) [2, 5] . Notably, platelet reference values do not vary across gestation [4] . We also extracted information on the mean platelet volume (MPV) and the maternal platelet count at first sampling. Chi-square or Fisher exact tests were used for categorical variables. Normality of continuous variables was checked with the Kolmogorov-Smirnov test and then parametric or nonparametric tests were used as appropriate. Correlations between opening and closing platelet counts were determined with Pearson's correlation coefficient.
The study was approved by the Washington University in St. Louis Human Research Protection Office. A waiver of consent was granted due to the retrospective and noninterventional nature of the study. Given that we included all women who met inclusion criteria and the sample size was fixed, we did not perform an a priori sample size calculation. Study data were collected and managed using REDCap electronic data capture tools hosted at Washington University School of Medicine in St. Louis [7] . Analyses were performed in SAS software (version 9.2; SAS Institute, Inc, Cary, NC). A p-value < 0.05 was considered statistically significant, and we did not adjust for multiple comparisons.
Systematic review and meta-analysis
A medical librarian (LES) searched published literature for records discussing fetal thrombocytopenia, fetal anemia, and fetal platelet count. The librarian created search strategies using a combination of keywords and controlled vocabulary in Ovid Medline 1946-, Embase.com 1947-, Scopus 1823-, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Protocols (Protocols), Cochrane Clinical Answers (ANSWERS), and Clinicaltrials.gov 1997 to present. Search results were limited to humans by excluding animals using the OVID Medline human filter recommended in the Cochrane Handbook for Systematic Reviews of Interventions. All search strategies were completed in September 2018 and were re-run in January 2019. In the updated search, all records published before January 1, 2018, were deleted leaving only 2018 and 2019 citations, and then duplicates were removed to locate new unique references. The full search strategies are detailed in the Supplemental Appendix.
We included English language articles published prior to January 2019 that were observational studies reporting on fetal thrombocytopenia or platelet count in pregnancies complicated by fetal anemia due to maternal alloimmunization. We excluded case reports and review articles, as well as articles detailing fetal thrombocytopenia due to other etiologies such as neonatal alloimmune thrombocytopenia or infection. The primary outcome was fetal thrombocytopenia.
Titles and abstracts were screened by the first author (JIR) and full-text articles were retrieved for all potentially relevant results. Full-text articles were reviewed against the inclusion criteria and then data from the eligible articles were extracted for presentation. We conducted a metaanalysis of proportion of thrombocytopenia at first PUBS procedure prior to any transfusion using the metaprop procedure in Stata IC/13.1, StataCorp, College Station, Texas [8] . The Freeman-Tukey Double arcsine transformation was performed and the random-effects model of DerSimonian and Laird was used [8] .
Results
Cohort study
There were 50 eligible patients ( Table 1 ). The median gestational age at first procedure was 25 weeks (interquartile range 20, 28). A total of 158 PUBS procedures were performed with 143 in utero transfusions. Opening platelet counts (range 8-485 × 10 9 /L) were available for 120 PUBS. Of these procedures, 71 (59%) had no thrombocytopenia, 36 (30%) had moderate thrombocytopenia, and 13 (11%) had severe thrombocytopenia. At first procedure, prior to any transfusion, 13/36 fetuses (36%) had thrombocytopenia, 11/36 (31%) had moderate thrombocytopenia, and 2/36 (6%) had severe thrombocytopenia (14 patients had no platelet count at first procedure). There were seven patients with fetal platelet count <100 × 10 8 /L at first procedure. At subsequent procedures the prevalence of thrombocytopenia was 36/84 (43%). Overall, 25 (50%) patients had fetal thrombocytopenia in at least one procedure. There were five patients with no recorded fetal platelet count at any procedure. Platelet counts varied over time and there were only three patients with platelet counts consistently <150 × 10 9 /L at all procedures. The MPV was normal (6.8-10.4 fl) in all 13 patients with fetal thrombocytopenia at first PUBS, with a median MPV of 7.8 fl (interquartile range 7.5, 7.9). There were five patients with maternal thrombocytopenia at time of first PUBS; of these 3 (60%) also had fetal thrombocytopenia, while the remaining 2 (40%) did not. Of the 13 cases of fetal thrombocytopenia, only 3/13 (23%) had concomitant maternal thrombocytopenia as well.
Procedural factors are noted in Table 2 . The mean hemoglobin in the thrombocytopenic group was 6.8 g/dL (standard deviation 2.8 g/dL); while in the nonthrombocytopenic group it was 8.1 g/dL (standard deviation 3.1 g/dL), p = 0.02. There were no associations between thrombocytopenia at the time of procedure and intraprocedural complications.
Thrombocytopenia was found during 16 (44%) of PUBS procedures (n = 36) in patients with anti-D antibodies only, in 10 (28%) of PUBS in patients with anti-D and other antibodies (n = 36), and in 23 (48%) of PUBS (n = 48) in patients with only other kinds of antibodies (p = 0.15). There was no association between antibody specificity and severe fetal thrombocytopenia (p = 0.27).
Outcomes stratified by thrombocytopenia status are in Table 3 . There was no association between antenatal thrombocytopenia and neonatal thrombocytopenia. However, it appeared that neonatal hemoglobin and gestational age at delivery were lower in the thrombocytopenic group, although this did not meet statistical significance. Finally, there were no adverse outcomes directly attributable to thrombocytopenia in the study population.
Systematic review
The search resulted in 3977 unique records which were included in the project library after excluding duplicates. In addition to these, 221 records were identified in ClinicalTrials.gov, resulting in a total of 4198 unique records. The reference lists of the selected articles were hand searched for further references, which revealed one additional source, yielding a total of 4199 citations [9] . The updated Figure 1 depicts the PRISMA Flow Diagram. After reviewing the titles and abstracts of each paper, 16 manuscripts (or abstracts if no full-text papers were available) were screened against the inclusion and exclusion criteria. Of these 16 studies, 9 were excluded for failing to meet inclusion criteria. Also the previously presented abstract of this article was excluded due to redundancy. In the end, six studies were included in the systematic review [2-5, 10, 11] . Table 4 includes a summary of the included studies. Most, but not all studies, defined thrombocytopenia as a platelet count <150 × 10 9 /L on first blood sampling at the time of PUBS or fetoscopic procedure. The forest plot is in Fig. 2 . The overall estimated proportion of fetuses with thrombocytopenia at the time of PUBS for Rh alloimmunization was 18% (95% confidence interval 11%, 26%). Excluding a Numbers represent n (%) or median (interquartile range) (n is the number of available patients for that datapoint)
P from Kruskal-Wallis or Fisher exact test Week correlation between fetal hemoglobin and fetal platelet count.
Thrombocytopenia more common in hydropic fetuses study that included only patients with anti-Kell antibodies did not substantially change this estimate (19, 95% confidence interval 12, 28%) [10] . Similarly, excluding the two studies that only assessed thrombocytopenia in anemic fetuses did not materially change the results [4, 11] .
Discussion
We found that fetal thrombocytopenia at the time of PUBS for suspected fetal anemia due to maternal alloimmunization was common, occurring in up to 40% of procedures and 50% of patients. Fetuses with more severe anemia were more likely to be thrombocytopenic. Platelet levels varied over time between procedures, with only a minority of patients having persistent thrombocytopenia. Finally, it appeared that neonatal hemoglobin and gestational age at delivery were lower in the thrombocytopenic group, although this did not meet statistical significance. The metaanalysis found that fetal thrombocytopenia complicates nearly 20% of initial PUBS in patients with maternal alloimmunization. However, the meta-analysis also noted significant heterogeneity in definitions of thrombocytopenia and associated outcomes. To our knowledge, there have not been any trials of platelet transfusion at the time of IUT in severely thrombocytopenic fetuses [2] . Our findings call into question whether treatment of fetal thrombocytopenia at the time of PUBS should be considered. However, such a policy would require platelets to be prepared for all fetuses, resulting in wasted platelets in 80% of cases. Furthermore, the balance between red blood cell transfusion and platelet transfusion is unclear, given that the addition of platelet transfusion would give extra volume to an already compromised fetus. It is also possible that correction of fetal thrombocytopenia would not affect outcomes in a meaningful way. In addition, in a recent randomized trial, neonatal platelet transfusion resulted in adverse outcomes in preterm infants [12] . Further investigation is needed to answer these questions.
Our study has a number of strengths. It is a single-center study employing a uniform protocol for IUT. We were able to assess fetal platelet counts over time in fetuses with multiple PUBS procedures. In addition, we were able to examine the associations between fetal thrombocytopenia and a number of procedural and outcomes factors. Finally, the systematic review and meta-analysis contextualize our findings.
On the other hand, there are some limitations to consider. The study was retrospective and therefore data were not available on outcomes in all pregnancies. In addition, hydrops was not uniformly recorded in the medical record and so we could not assess the relationship between thrombocytopenia and hydrops at the time of procedure. Furthermore, our samples are collected in heparinized syringes; these are heparinized by the physician at the time of the procedure. The use of heparin may have altered platelet counts in the samples. Finally, our sample size was relatively small, which limited our statistical power. To date the mechanism of fetal thrombocytopenia in alloimmunized pregnancies has not been elucidated. It is postulated that more anemic fetuses may have increased consumption or destruction of platelets [2] . Alternatively, hematopoiesis may be directed toward red-cell production, thus decreasing production of platelets [2] . The fact that the MPV was normal in all patients with fetal thrombocytopenia at first PUBS may point to decreased production, rather than increased consumption, as the underlying etiology [13] . In fact, neonatal thrombocytopenia and neutropenia are seen in severely affected neonates with Rh hemolytic disease, and these neonates also have low or normal MPV, again suggesting decreased production as opposed to increased consumption of platelets [14] . On the other hand, of the five mothers with maternal thrombocytopenia, three had fetal thrombocytopenia and two did not, suggesting that maternal thrombocytopenia, possibly antibody mediated, may be a risk factor for fetal thrombocytopenia in alloimmunized patients, although the numbers are very small to make any definitive conclusions. Although IUT can suppress hematopoiesis, since the studies here are mostly limited to the first PUBS prior to IUT, this would not explain the thrombocytopenia seen at the first PUBS [2] . The coexistence of fetal thrombocytopenia and fetal anemia in alloimmunized pregnancies has been now observed for nearly 30 years [5] . It is time to move to the next step and further investigate the underlying mechanisms and potential consequences of this finding.
